The prognostic value of baseline CD4+ cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting

AIDS

Volumn 26, Issue 11, 2012, Pages 1425-1429

  Mills, Edward J ^a   Bakanda, Celestin ^b   Birungi, Josephine ^b   Yaya, Sanni ^a   Ford, Nathan ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b THE AIDS SUPPORT ORGANIZATION   (Uganda)

^c Medecins Sans Frontiers   (Switzerland)

Author keywords

antiretroviral therapy; CD4+; HIV; prognosis; sub Saharan Africa; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; EARLY INTERVENTION; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SELF REPORT; TREATMENT DURATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEX DISTRIBUTION; UGANDA; VIRAL LOAD;

EID: 84863726671     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328354bf43     Document Type: Article

References (26)

1. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577. (Pubitemid 33096808)
2. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
3. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
4. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
5. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. http://whqlibdocwhoint/publications/2010/9789241599764-engpdf; 2010.
6. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376:449-457.
7. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006; 367:817-824.
8. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
9. van Griensven J, Thai S. Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hygiene 2011; 105:694-703.
10. Bakanda C, Birungi J, Nkoyooyo A, Featherstone A, Cooper CL, Hogg RS, et al. Cohort profile: the TASO-CAN cohort collaboration. Int J Epidemiol 2011.
11. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25:851-855.
12. Bakanda C, Birungi J, Mwesigwa R, Zhang W, Hagopian A, Ford N, et al. Density of healthcare providers and patient outcomes: evidence from a nationally representative multisite HIV treatment program in Uganda. PLoS One 2011; 6:e16279.
13. Bakanda C, Birungi J, Mwesigwa R, Ford N, Cooper CL, Au-Yeung C, et al. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 2011; 25:701-705.
14. Geng EH, Emenyonu N, Bwana MB, Glidden DV. Martin JN Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008; 300:506-507.
15. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pretreatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9:290.
16. Allison PD. Survival analysis using SAS: a practical guide. Cary, NC: SAS Institute Inc.; 1995.
17. Yuan YC. Multiple imputation for missing data: concepts and new development (Version 9.0). Rockville, MD: SAS Institute Inc.
18. Jaffar S. Reduction of early mortality among HIV-infected subjects starting antiretroviral therapy (REMSTART): a randomised trial. Ongoing. http://wwwlshtmacuk/eph/ide/research/teg/research hiv-research- teghtml#Reductionofearlymortalitya mongHIV- infectedsubjectsstartingantiretroviraltherapyREMST ART:arandomisedtrial. 2012.
19. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011; 14:52.
20. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Inter Med 2011; 155:209-216.
21. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One 2011; 6:e19261.
22. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Women's Health 2008; 17:47-55. (Pubitemid 351197536)
23. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive: trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 2009; 38:287-298.
24. Geng EH, Bwana MB, Kabakyenga J, Muyindike W, Emenyonu NI, Musinguzi N, et al. Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One 2010; 5:e14098.
25. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
26. Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, et al. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010; 24:1929-1935.